Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The cancer bloodhounds.

Literature DB >> 27824838

The cancer bloodhounds.

Sarah Webb.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27824838 DOI： 10.1038/nbt.3717

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

8 in total

1. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Authors: Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner
Journal: Sci Transl Med Date: 2015-08-26 Impact factor: 17.956

2. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors: Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal: Nat Med Date: 2015-06-01 Impact factor: 53.440

3. Exosome cancer diagnostic reaches market.

Authors: Cormac Sheridan
Journal: Nat Biotechnol Date: 2016-04 Impact factor: 54.908

4. Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956

5. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956

6. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors: Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777

7. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.

Authors: Filip Janku; Cecile Rose T Vibat; Karena Kosco; Veronica R Holley; Goran Cabrilo; Funda Meric-Bernstam; Vanda M Stepanek; Patrick P Lin; Lorieta Leppin; Latifa Hassaine; Jason C Poole; Razelle Kurzrock; Mark G Erlander
Journal: Oncotarget Date: 2014-06-15

8. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Authors: Maria Schwaederle; Hatim Husain; Paul T Fanta; David E Piccioni; Santosh Kesari; Richard B Schwab; Kimberly C Banks; Richard B Lanman; AmirAli Talasaz; Barbara A Parker; Razelle Kurzrock
Journal: Oncotarget Date: 2016-03-01

8 in total

21 in total

1. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

Authors: Karinna Almodovar; Wade T Iams; Catherine B Meador; Zhiguo Zhao; Sally York; Leora Horn; Yingjun Yan; Jennifer Hernandez; Heidi Chen; Yu Shyr; Lee P Lim; Christopher K Raymond; Christine M Lovly
Journal: J Thorac Oncol Date: 2017-09-23 Impact factor: 15.609

2. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.

Authors: Colin M Court; Shuang Hou; Lian Liu; Paul Winograd; Benjamin J DiPardo; Sean X Liu; Pin-Jung Chen; Yazhen Zhu; Matthew Smalley; Ryan Zhang; Saeed Sadeghi; Richard S Finn; Fady M Kaldas; Ronald W Busuttil; Xianghong J Zhou; Hsian-Rong Tseng; James S Tomlinson; Thomas G Graeber; Vatche G Agopian
Journal: NPJ Precis Oncol Date: 2020-07-02

The cancer bloodhounds.

1. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

2. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

3. Exosome cancer diagnostic reaches market.

4. Detection of circulating tumor DNA in early- and late-stage human malignancies.

5. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

6. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

7. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.

8. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

1. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

2. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.

3. Erratum: The cancer bloodhounds.

4. Grail to pour $1 billion into blood test to detect early cancer.

Review 5. Liquid Biopsy to Identify Actionable Genomic Alterations.

6. An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection.

7. Jury out on liquid biopsies for cancer.

8. Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.

Review 9. Tumour-adipose tissue crosstalk: fuelling tumour metastasis by extracellular vesicles.

Review 10. Tumor circulome in the liquid biopsies for digestive tract cancer diagnosis and prognosis.